Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route

Fig. 4

asTCR lentivirus production and Tranilast dose–response curve. a Framework of αβTCR transgene. The αTCR and βTCR consisting of the leader peptide, variable, and constant genes were separated by a 2A cleavage peptide. b and c amplified asTCR transgenes of about 2.2 kb size and their respective dimeric lentivector clones. Lanes T1 to T0 represent TCR1 to TCR0, respectively. d Titration of asTCR lentiviruses after transducing J.RT3-T3.5 cells. Lentivirus was titered using TCRβ antibody in a flow cytometry analysis. e–g Hillslope representing the diagrammatic representation of Tranilast dose–response relationship on ECA109(NY-ESO-1−/HLA-A*02:01−) (e), ECA109(NY-ESO-1+/HLA-A*02:01+) (f), and OE19(NY-ESO-1+/HLA-A*02:01+) (g) EC cell lines

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us